Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of "Buy" from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received an average recommendation of "Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $32.50.

Several analysts recently commented on the stock. Stephens reissued an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Bank of America reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd.

Remove Ads

Catalyst Pharmaceuticals Stock Up 2.5 %

Catalyst Pharmaceuticals stock traded up $0.56 during midday trading on Monday, hitting $23.16. The company's stock had a trading volume of 1,092,935 shares, compared to its average volume of 1,044,002. Catalyst Pharmaceuticals has a 12 month low of $14.47 and a 12 month high of $24.64. The company has a market capitalization of $2.81 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock's 50-day moving average price is $22.34 and its 200-day moving average price is $21.57.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $29,000. Farther Finance Advisors LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. Institutional investors own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.